Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 22, 2026 |
| NCT06881823 | Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC(NeoPSMA) | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 29, 2025 | clinicaltrials |
| NCT03477864 | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06218667 | A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Oct 31, 2024 | clinicaltrials |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | withdrawn | Phase 1 / Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | May 2, 2024 | clinicaltrials |
| NCT04879589 | Phase 1 Study of ATRS-2002 in Healthy Male Adults | withdrawn | Phase 1 | 0 | Syneos HealthOTHER | 0 | Apr 28, 2023 | clinicaltrials |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT05191017 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | withdrawn | Phase 1 / Phase 2 | 0 | Nuvation Bio Inc.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01826838 | Study of Dasatinib, Androgen Deprivation Therapy and Radiation(BrUOGPR255) | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 0 | Feb 24, 2022 | clinicaltrials |
| NCT04296578 | Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone | withdrawn | Phase 1 | 0 | Stanford UniversityOTHER | 0 | Aug 12, 2021 | clinicaltrials |
| NCT03110588 | Phase I Trial of PACE for Metastatic Prostate Cancer | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01079793 | Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT02647983 | Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection | withdrawn | Phase 1 | 0 | Sunnybrook Health Sciences CentreOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02182622 | LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel | withdrawn | Phase 1 | 0 | Martin GutierrezOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT03465345 | Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients | withdrawn | Phase 1 | 0 | Medical University of South CarolinaOTHER | 1 | Aug 3, 2018 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT00937417 | S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Apr 24, 2017 | clinicaltrials |
| NCT02396368 | A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer(Radium-223) | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT01685489 | A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer | withdrawn | Phase 1 | 0 | Bastyr UniversityOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT01163448 | Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 6, 2015 | clinicaltrials |
| NCT01565512 | Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort | withdrawn | Phase 1 / Phase 2 | 0 | Columbia UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01320787 | 18-F-Fluoroacetate as PET Imaging Agent | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 23, 2014 | clinicaltrials |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) | withdrawn | Phase 1 / Phase 2 | 0 | Emmanuel Antonarakis, MDOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT01981668 | The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation | withdrawn | Phase 1 | 0 | Nova Scotia Cancer CentreOTHER | 0 | Mar 19, 2014 | clinicaltrials |
| NCT00110526 | Gene Therapy for Prostate Cancer That Returns After Radiation Therapy | withdrawn | Phase 1 | 0 | Simon HallOTHER | 0 | Oct 24, 2013 | clinicaltrials |
| NCT01197209 | Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer | withdrawn | Phase 1 | 0 | Momotaro-Gene Inc.INDUSTRY | 1 | Aug 23, 2013 | clinicaltrials |
| NCT00691977 | Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT00005827 | Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer | withdrawn | Phase 1 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 24, 2012 | clinicaltrials |
| NCT01153113 | Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines | withdrawn | Phase 1 / Phase 2 | 0 | University of FloridaOTHER | 0 | Dec 2, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Aug 28, 2026source: clinicaltrials